Shopping Cart 0
Cart Subtotal
USD 0

Pharmaceuticals in Australia

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Pharmaceuticals in Australia

Summary

Pharmaceuticals in Australia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Australia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Australian pharmaceuticals market had total revenues of USD 24.2bn in 2017, representing a compound annual growth rate (CAGR) of 2.5% between 2013 and 2017.

- Factors driving growth in Australia's pharmaceuticals market are similar to many other developed markets, including an increasingly elderly population and its associated disease burden.

- The subsidized cost of prescription medication through Australia's Pharmaceutical Benefits Scheme (PBS) for eligible patients has helped drive growth in the market by making these products more widely available.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Australia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Australia

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Australia pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Australia pharmaceuticals market by value in 2017?

- What will be the size of the Australia pharmaceuticals market in 2022?

- What factors are affecting the strength of competition in the Australia pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in Australia's pharmaceuticals market?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market Segmentation 10

Geography segmentation 10

Market share 11

Market Outlook 12

Market value forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 16

New entrants 18

Threat of substitutes 20

Degree of rivalry 21

Leading Companies 23

Aspen Pharmacare Holdings Ltd 23

AstraZeneca PLC 27

GlaxoSmithKline Plc 30

Pfizer Inc. 34

Macroeconomic Indicators 38

Country data 38

Methodology 40

Industry associations 41

Related MarketLine research 41

Appendix 42

About MarketLine 42


List Of Figure

List of Figures

Figure 1: Australia pharmaceuticals market value: USD billion, 2013-17

Figure 2: Australia pharmaceuticals market geography segmentation: % share, by value, 2017

Figure 3: Australia pharmaceuticals market share: % share, by value, 2017

Figure 4: Australia pharmaceuticals market value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the pharmaceuticals market in Australia, 2017

Figure 6: Drivers of buyer power in the pharmaceuticals market in Australia, 2017

Figure 7: Drivers of supplier power in the pharmaceuticals market in Australia, 2017

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Australia, 2017

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Australia, 2017

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Australia, 2017

Figure 11: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 12: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 13: AstraZeneca PLC: revenues & profitability

Figure 14: AstraZeneca PLC: assets & liabilities

Figure 15: GlaxoSmithKline Plc: revenues & profitability

Figure 16: GlaxoSmithKline Plc: assets & liabilities

Figure 17: Pfizer Inc.: revenues & profitability

Figure 18: Pfizer Inc.: assets & liabilities


List Of Table

List of Tables

Table 1: Australia pharmaceuticals market value: USD billion, 2013-17

Table 2: Australia pharmaceuticals market geography segmentation: USD billion, 2017

Table 3: Australia pharmaceuticals market share: % share, by value, 2017

Table 4: Australia pharmaceuticals market value forecast: USD billion, 2017-22

Table 5: Aspen Pharmacare Holdings Ltd: key facts

Table 6: Aspen Pharmacare Holdings Ltd: key financials (USD )

Table 7: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 8: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 9: AstraZeneca PLC: key facts

Table 10: AstraZeneca PLC: key financials (USD )

Table 11: AstraZeneca PLC: key financial ratios

Table 12: GlaxoSmithKline Plc: key facts

Table 13: GlaxoSmithKline Plc: key financials (USD )

Table 14: GlaxoSmithKline Plc: key financials (GBP)

Table 15: GlaxoSmithKline Plc: key financial ratios

Table 16: Pfizer Inc.: key facts

Table 17: Pfizer Inc.: key financials (USD )

Table 18: Pfizer Inc.: key financial ratios

Table 19: Australia size of population (million), 2013-17

Table 20: Australia gdp (constant 2005 prices, USD billion), 2013-17

Table 21: Australia gdp (current prices, USD billion), 2013-17

Table 22: Australia inflation, 2013-17

Table 23: Australia consumer price index (absolute), 2013-17

Table 24: Australia exchange rate, 2013-17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Pharmaceuticals in Australia

Summary

Pharmaceuticals in Australia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Australia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Australian pharmaceuticals market had total revenues of USD 24.2bn in 2017, representing a compound annual growth rate (CAGR) of 2.5% between 2013 and 2017.

- Factors driving growth in Australia's pharmaceuticals market are similar to many other developed markets, including an increasingly elderly population and its associated disease burden.

- The subsidized cost of prescription medication through Australia's Pharmaceutical Benefits Scheme (PBS) for eligible patients has helped drive growth in the market by making these products more widely available.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Australia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Australia

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Australia pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Australia pharmaceuticals market by value in 2017?

- What will be the size of the Australia pharmaceuticals market in 2022?

- What factors are affecting the strength of competition in the Australia pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in Australia's pharmaceuticals market?

READ MORE

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market Segmentation 10

Geography segmentation 10

Market share 11

Market Outlook 12

Market value forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 16

New entrants 18

Threat of substitutes 20

Degree of rivalry 21

Leading Companies 23

Aspen Pharmacare Holdings Ltd 23

AstraZeneca PLC 27

GlaxoSmithKline Plc 30

Pfizer Inc. 34

Macroeconomic Indicators 38

Country data 38

Methodology 40

Industry associations 41

Related MarketLine research 41

Appendix 42

About MarketLine 42


List Of Figure

List of Figures

Figure 1: Australia pharmaceuticals market value: USD billion, 2013-17

Figure 2: Australia pharmaceuticals market geography segmentation: % share, by value, 2017

Figure 3: Australia pharmaceuticals market share: % share, by value, 2017

Figure 4: Australia pharmaceuticals market value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the pharmaceuticals market in Australia, 2017

Figure 6: Drivers of buyer power in the pharmaceuticals market in Australia, 2017

Figure 7: Drivers of supplier power in the pharmaceuticals market in Australia, 2017

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Australia, 2017

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Australia, 2017

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Australia, 2017

Figure 11: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 12: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 13: AstraZeneca PLC: revenues & profitability

Figure 14: AstraZeneca PLC: assets & liabilities

Figure 15: GlaxoSmithKline Plc: revenues & profitability

Figure 16: GlaxoSmithKline Plc: assets & liabilities

Figure 17: Pfizer Inc.: revenues & profitability

Figure 18: Pfizer Inc.: assets & liabilities


List Of Table

List of Tables

Table 1: Australia pharmaceuticals market value: USD billion, 2013-17

Table 2: Australia pharmaceuticals market geography segmentation: USD billion, 2017

Table 3: Australia pharmaceuticals market share: % share, by value, 2017

Table 4: Australia pharmaceuticals market value forecast: USD billion, 2017-22

Table 5: Aspen Pharmacare Holdings Ltd: key facts

Table 6: Aspen Pharmacare Holdings Ltd: key financials (USD )

Table 7: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 8: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 9: AstraZeneca PLC: key facts

Table 10: AstraZeneca PLC: key financials (USD )

Table 11: AstraZeneca PLC: key financial ratios

Table 12: GlaxoSmithKline Plc: key facts

Table 13: GlaxoSmithKline Plc: key financials (USD )

Table 14: GlaxoSmithKline Plc: key financials (GBP)

Table 15: GlaxoSmithKline Plc: key financial ratios

Table 16: Pfizer Inc.: key facts

Table 17: Pfizer Inc.: key financials (USD )

Table 18: Pfizer Inc.: key financial ratios

Table 19: Australia size of population (million), 2013-17

Table 20: Australia gdp (constant 2005 prices, USD billion), 2013-17

Table 21: Australia gdp (current prices, USD billion), 2013-17

Table 22: Australia inflation, 2013-17

Table 23: Australia consumer price index (absolute), 2013-17

Table 24: Australia exchange rate, 2013-17

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com